BHC
Bausch Health·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
High Gross Profit Margin
Significant Net Income Growth
High Cash/net Profit Ratio
Revenue Beats Expectation
RSI Overbought
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BHC
Bausch Health Companies Inc.
A global diversified pharmaceutical company that develops branded drugs in the areas of dermatology, neurolog and eye health and OTC products
2150 St. Elzear Blvd. West, Laval, Quebec, Canada, H7L 4A8B
--
Bausch Health Companies Inc. is a company incorporated in British Columbia, Canada. The Company is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and sells a wide range of branded, generic and branded generic drugs, over-the-counter drug products and medical beauty devices in the therapeutic areas of gastroenterology and dermatology, and through its approximately 89% ownership of Bausch + Lomb Corporation, Develop branded and branded generic drugs, over-the-counter drug products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical devices) in the field of eye health treatment. The company's products are sold directly or indirectly in about 100 countries.
Earnings Call
Q2/2025
Estimate EPS0.94
Actual EPS0.4
Estimate Revenue2.49B
Actual Revenue2.53B
Xifaxan's 2025 Earnings Call: Unpacking Contradictions in IRA Impact, Capital Strategy, and DTC Focus
Jul 31,2025 12:59
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS1.06
Actual EPS0.48
Estimate Revenue2.63B
Actual Revenue2.68B
Bausch Health's Q3 2025: Contradictions Emerge on Xifaxan Revenue vs. Prescriptions, EBITDA Margins, Manufacturing, and 340B/Medicaid Exit
Oct 30,2025 03:47
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
BHC has released its 2025 Q3 earnings. EPS was reported at 0.48, versus the expected 1.06, missing expectations. The chart below visualizes how BHC has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BHC has released its 2025 Q3 earnings report, with revenue of 2.68B, reflecting a YoY change of 6.81%, and net profit of 181.00M, showing a YoY change of 296.74%. The Sankey diagram below clearly presents BHC's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
